SomnoMed Limited (ASX:SOM)

Market Cap	63.73M -61.1%
Revenue (ttm)	114.53M +2.7%
Net Income	-2.65M
EPS	-0.01
Shares Out	219.77M
PE Ratio	n/a
Forward PE	14.83
Dividend	n/a
Ex-Dividend Date	n/a

Volume	62,956
Open	0.3000
Previous Close	0.2900
Day's Range	0.2900 - 0.3000
52-Week Range	0.2900 - 0.9450
Beta	0.83
Analysts	Strong Buy
Price Target	0.84 (+189.66%)
Earnings Date	Aug 28, 2026

About SomnoMed

SomnoMed Limited, together with its subsidiaries, produce and sells devices for the oral treatment of sleep related disorders in the Asia Pacific region, North America, and Europe. The company offers SomnoDent, such as SomnoDent Avant, SomnoDent Classic, SomnoDent Flex, herbst advance, and SomnoDent Fusion for the treatment of obstructive sleep apnea. It also provides SomMorning Repositioner, a product designed to help return patient’s mandible back to its pre-treatment centric position; SomnoBrux splint, a custom fit, acrylic splint for patien...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1987
• Employees: 300
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: SOM

Financial Performance

In fiscal year 2026, SomnoMed's revenue was 114.53 million, an increase of 2.73% compared to the previous year's 111.49 million. Losses were -2.65 million, -23.32% less than in 2025.

Analyst Summary

According to 3 analysts, the average rating for SOM stock is "Strong Buy." The 12-month stock price target is $0.84, which is an increase of 189.66% from the latest price.

Price Target

$0.84

(189.66% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 7, 2026

Data Sources Report a data error